Β-Thalassemia Treatment with KL003 Cell Injection
Clinical trial NCT06280378 · RECRUITING
Trial details
- NCT number
- NCT06280378
- Sponsor
- Kanglin Biotechnology (Hangzhou) Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-05
- Primary completion
- 2025-10-01
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.